Implementation of the first worldwide quality assurance program for cystic fibrosis multiple mutation detection in population-based screening

Results show that laboratories using molecular assays to detect CFTR mutations are performing satisfactorily. The programmatic results presented demonstrate the importance and complexity of providing proficiency testing for DNA-based assays.